Target
Growth hormone receptor
Description
Anti-Growth hormone receptor Antibody, Non-Fucosylated (BioBet-922ZP) is a human monoclonal IgG antibody against Growth hormone receptor. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Growth hormone receptor antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
GDNF family receptor alpha 3
Background
This gene encodes a member of the type I cytokine receptor family, which is a transmembrane receptor for growth hormone. Binding of growth hormone to the receptor leads to receptor dimerization and the activation of an intra- and intercellular signal transduction pathway leading to growth. Mutations in this gene have been associated with Laron syndrome, also known as the growth hormone insensitivity syndrome (GHIS), a disorder characterized by short stature. In humans and rabbits, but not rodents, growth hormone binding protein (GHBP) is generated by proteolytic cleavage of the extracellular ligand-binding domain from the mature growth hormone receptor protein. Multiple alternatively spliced transcript variants have been found for this gene.
Alternative Names
GHR; growth hormone receptor; GHBP; GH receptor; serum binding protein; somatotropin receptor; growth hormone binding protein
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with GHR include Laron Syndrome and Growth Hormone Insensitivity, Partial.
Related Pathways
Its related pathways are Relaxin signaling pathway and PEDF Induced Signaling.
Function
The pituitary growth hormone receptor is involved in regulating body growth after birth. In ligand binding, it binds to the JAK2/STAT5 pathway (through similarity). The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of growth hormone signal. Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.
Post-translational modifications
The soluble form (GHBP) is produced by phorbol ester-promoted proteolytic cleavage at the cell surface (shedding) by ADAM17/TACE. Shedding is inhibited by growth hormone (GH) binding to the receptor probably due to a conformational change in GHR rendering the receptor inaccessible to ADAM17 (By similarity). On GH binding, phosphorylated on tyrosine residues in the cytoplasmic domain by JAK2. On ligand binding, ubiquitinated on lysine residues in the cytoplasmic domain. This ubiquitination is not sufficient for GHR internalization (By similarity).
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-922ZP
Description
The antibody binding to human growth hormone receptor (GHR) can be used therapeutically to lower IGF-1 levels in plasma and/or tissue, and can be used in the prevention and/or treatment of cancer, diabetic nephropathy, arthritis, lung inflammation, and growth disorders, including acromegaly and gigantism.
Antibody Indication
Cancer
